FDA Expects Mifepristone Safety Review Results By March
The U.S. Food and Drug Administration anticipates finishing its safety evaluation of mifepristone by March 2027, suggesting a longer horizon for its review of regulations allowing the abortion drug to be...To view the full article, register now.
Already a subscriber? Click here to view full article